Maxim Group restated their buy rating on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research report released on Wednesday morning. The brokerage currently has a $14.00 target price on the biopharmaceutical company’s stock.
A number of other brokerages also recently commented on ABEO. HC Wainwright reissued a buy rating and issued a $17.00 price objective on shares of Abeona Therapeutics in a research report on Thursday, October 6th. Cantor Fitzgerald reissued a buy rating and issued a $21.00 price objective on shares of Abeona Therapeutics in a research report on Friday, September 23rd. FBR & Co reissued a positive rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research report on Wednesday, October 5th. Finally, Zacks Investment Research cut shares of Abeona Therapeutics from a hold rating to a sell rating in a research note on Monday, September 12th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Abeona Therapeutics presently has an average rating of Buy and a consensus target price of $14.50.
Shares of Abeona Therapeutics (NASDAQ:ABEO) opened at 6.74 on Wednesday. Abeona Therapeutics has a 52 week low of $2.05 and a 52 week high of $7.19. The company’s market capitalization is $226.09 million. The firm’s 50-day moving average is $5.57 and its 200 day moving average is $3.54.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.06. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. On average, analysts anticipate that Abeona Therapeutics will post ($0.73) earnings per share for the current fiscal year.
In other Abeona Therapeutics news, Director Todd Wider acquired 5,000 shares of the company’s stock in a transaction on Tuesday, September 20th. The stock was acquired at an average price of $5.48 per share, for a total transaction of $27,400.00. Following the purchase, the director now directly owns 75,000 shares of the company’s stock, valued at $411,000. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 13.00% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Sabby Management LLC boosted its stake in shares of Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock valued at $855,000 after buying an additional 34,108 shares during the period. Geode Capital Management LLC boosted its stake in shares of Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 10,082 shares during the period. Finally, Royce & Associates LP boosted its stake in shares of Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 76,678 shares during the period. Institutional investors and hedge funds own 19.95% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.